Pre-Tax Income: Company's earnings or loss before taxes on income have been accounted for.
Enliven Therapeutics, Inc. (ELVN) had Pre-Tax Income of $-28.54M for the most recently reported fiscal quarter, ending 2025-03-31.
| Income Statement Financials | |
-- |
|
$-28.54M |
|
-- |
|
-- |
|
$31.69M |
|
$-31.69M |
|
$3.15M |
|
|
Pre-Tax Income |
$-28.54M |
$-28.54M |
|
$-28.54M |
|
$-28.54M |
|
$-28.54M |
|
$-28.54M |
|
$-31.69M |
|
$-31.66M |
|
50.05M |
|
50.05M |
|
$-0.57 |
|
$-0.57 |
|
| Balance Sheet Financials | |
$294.32M |
|
$0.40M |
|
$8.25M |
|
$302.57M |
|
$13.97M |
|
-- |
|
$0.30M |
|
$14.27M |
|
$288.30M |
|
$288.30M |
|
$288.30M |
|
49.04M |
|
| Cash Flow Statement Financials | |
$-24.13M |
|
$1.43M |
|
$0.23M |
|
$124.17M |
|
$101.70M |
|
$-22.47M |
|
$6.80M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
21.06 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-24.15M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-9.90% |
|
-9.90% |
|
-9.43% |
|
-9.90% |
|
$5.88 |
|
$-0.48 |
|
$-0.48 |
|